KOSDAQBiotech & Pharma216080

Jetema

₩5,560▲ 1.09%2026-11-18 close
Market Cap
₩207.3B
Turnover
₩200M
Volume
40K
Shares out.
37.3M
PER
—
PBR
2.9×
EPS
-₩53
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Jetema: Profit Recovery Tested by Overseas Toxin and Filler Expansion

Jetema kept posting operating profit in the second and third quarters of 2026, but its net loss attributable to controlling shareholders widened in the third quarter. Whether the recovery reaches net income is the key open question.

  1. 1

    Operating profit turned to KRW 2.31 billion in the second quarter of 2026 and reached KRW 1.42 billion in the third quarter, up 39.2% from a year earlier. The company credited lower manufacturing and SG&A cost ratios.

  2. 2

    Net loss attributable to controlling shareholders was KRW 3.81 billion in the third quarter of 2026, a wider loss than a year earlier. The four-quarter total from Q4 2025 to Q3 2026 was KRW 2.06 billion.

  3. 3

    Overseas sales accounted for 62.5% of revenue in the first quarter of 2026. Commercial botulinum toxin shipments to Thailand have started to feed into results, while approval procedures in China and Brazil are in progress.

  4. 4

    Total liabilities were KRW 144.1 billion at the end of 2025, with a debt-to-equity ratio of 221.7%. Operating cash flow recovered to KRW 11.1 billion in 2025 from KRW 3.72 billion in 2024.

  5. 5

    PER cannot be calculated because the last four quarters were net losses, and the share price sits at a premium to book value.

02

Business structure

Jetema is a medical aesthetics company whose core products are hyaluronic acid fillers and botulinum toxin. Its flagship filler, e.p.t.q, was approved in more than 80 countries, according to the company's January 2026 announcement.

The toxin business gained momentum after the domestic launch of JETEMA THE TOXIN in April 2025, and in Thailand the product received marketing approval in June 2026 with commercial shipments following.

In the first quarter of 2026, medical device items such as hyaluronic acid fillers accounted for KRW 8.8 billion, or 55% of sales. Pharmaceutical items, including botulinum toxin, contributed KRW 5 billion, or 31%, and lifting threads, cosmetics and other items made up KRW 2.2 billion, or 14%.

Overseas sales in the same quarter were KRW 10 billion, a 62.5% share. In China, the company works with its partner Hwadong Aesthetics, and a 2025 report described a five-year distribution and promotion contract worth KRW 40 billion.

The company is preparing a botulinum toxin marketing application and commercialization there. In Brazil, ANVISA completed an inspection of the Wonju production site in July 2026, and local product approval procedures are under way.

On production, the company said it completed a cGMP system at its Wonju plant and expanded filler capacity. Jetema has five consolidated subsidiaries at home and abroad, and all five were loss-making in the first quarter of 2026, with JETEMA USA INC. posting the largest net loss at KRW 500 million. In toxins, the company competes with established domestic players such as Hugel.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩20.1B₩1B5.1%
2025Q4₩20.4B₩1.2B5.8%
2026Q1₩16B-₩700M−4.2%
2026Q2₩20.1B₩2.3B11.5%
2026Q3₩18.9B₩1.4B7.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩46B₩4B₩1.5B8.7%2.6%230.8%
2023₩58.7B₩2.6B₩14B4.5%19.5%234.3%
2024₩68.5B₩4.1B-₩200M6.0%−0.3%211.8%
2025₩76.9B₩3.8B-₩6.6B5.0%−10.1%221.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

In the annual filings, revenue rose from KRW 46 billion in 2022 to KRW 58.7 billion in 2023 (up 27.7% year on year), KRW 68.5 billion in 2024 (up 16.7%), and KRW 76.9 billion in 2025 (up 12.2%). Revenue has increased for three consecutive years from 2023 through 2025.

Operating profit moved in both directions over the same period: KRW 4.01 billion in 2022, KRW 2.63 billion in 2023 (down 34.3%), KRW 4.11 billion in 2024 (up 56.1%), and KRW 3.82 billion in 2025 (down 7.1%).

The operating margin fell from 8.7% in 2022 to 4.5% in 2023, then recovered to 6.0% in 2024 and 5.0% in 2025, still below the 2022 level. The company attributed the 2025 operating profit decline to a temporary rise in expenses, and cited growth in global filler sales as the driver of higher revenue.

Net income attributable to controlling shareholders reached KRW 14 billion in 2023, but turned to a net loss of KRW 188 million in 2024 and widened to a net loss of KRW 6.6 billion in 2025.

Net income including non-controlling interests was a loss of KRW 2.61 billion in 2024 and KRW 7.44 billion in 2025, two consecutive years of losses. The company explained the 2025 net loss widening with lower tax benefits from deferred tax changes.

Operating cash flow fell from KRW 14.2 billion in 2022 to KRW 3.72 billion in 2024 before recovering to KRW 11.1 billion in 2025.

In quarterly filings, the third quarter of 2025 showed revenue of KRW 20.1 billion and operating profit of KRW 1.02 billion, while the first quarter of 2026 swung to revenue of KRW 16 billion and an operating loss of KRW 665 million.

The second quarter of 2026 returned to operating profit of KRW 2.31 billion on revenue of KRW 20.1 billion. Third-quarter revenue of KRW 18.9 billion fell 6.1% year on year, while operating profit of KRW 1.42 billion rose 39.2%.

The net loss attributable to controlling shareholders in the third quarter of 2026 was KRW 3.81 billion, a wider loss than a year earlier.

05

Industry analysis

Fillers and toxins are demand-driven aesthetic markets, but Jetema's results depend more on overseas approval timing and partner shipment pace than on demand alone. In its 2025 results explanation, the company cited the ongoing Russia-Ukraine war, US-China trade tensions and a high exchange rate as headwinds.

Yakup, a trade publication, analyzed that first-quarter 2026 sales of medical device items such as fillers fell 34% from the prior quarter and 2% from a year earlier.

Pharmaceutical items, including botulinum toxin, rose 17% from the prior quarter and 22% from a year earlier, to KRW 5 billion, and their share of sales climbed to 31%. In toxins, Jetema follows established domestic players such as Hugel. Its domestic launch came in April 2025 and its Thai approval in June 2026.

In fillers, the company said it began full-scale exports to China after receiving a Class 3 approval from China's NMPA, working through its local partner. China requires both approval procedures and distribution capability, and in Brazil the timing of ANVISA approval determines when sales can begin.

Five consolidated subsidiaries were all loss-making in the first quarter of 2026, which shows that overseas expansion costs have not yet turned into profit.

06

Outlook

The company set a target of KRW 100 billion in revenue for 2026. According to a report on its quarterly filing, cumulative revenue for the first three quarters of 2026 was KRW 54.98 billion, so the gap to the target must be closed through overseas shipments and new approvals in the remaining period.

The company said it will focus on capturing the fourth-quarter peak season and expanding global business. In Thailand, commercial volumes have been feeding into results in sequence since the second half, following the June 2026 approval.

In China, Jetema is preparing a botulinum toxin marketing application and commercialization with its partner, and the company names China and Brazil as the key markets for future overseas sales. In Brazil, ANVISA completed its inspection in July 2026, and local product approval procedures are under way.

The company noted that approval timing, commercialization schedules and initial supply volumes in both markets will affect results. In the United States, its 2026 plan includes advancing a Phase 3 botulinum toxin trial, pursuing global licensing out, and building a direct sales network.

The company has set a long-term goal of becoming a global company with KRW 1 trillion in revenue within ten years. These targets depend on approvals and partner execution, and the 2026 annual report will show the first full-year filed figures against the target.

07

Valuation

PER
—
PBR
2.9×
ROE
-2.9%
EPS
-₩53
BPS
₩2,076
Dividend per share
₩0

The share price currently sits at a premium to book value. Because the last four quarters were net losses attributable to controlling shareholders, the price-to-earnings ratio cannot be calculated, and earnings-based multiple comparisons only become meaningful after profits persist for a period.

The company does not pay dividends, so a dividend yield comparison with its industry is not applicable.

Third-quarter 2026 operating profit rose year on year, but the net loss attributable to controlling shareholders widened, so how the market weighs the operating improvement against the net-level loss is central to interpreting the multiple.

Total liabilities at the end of 2025 were KRW 144.1 billion, with a debt-to-equity ratio of 221.7%, and that debt load is part of the valuation discussion. Operating cash flow recovering to KRW 11.1 billion in 2025 points to better cash generation, separate from net income.

Interpretation of the multiple therefore depends on whether profits persist and whether overseas sales actually grow.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Operating profit has stayed positive

After an operating loss of KRW 665 million in the first quarter of 2026, operating profit returned to KRW 2.31 billion in the second quarter and reached KRW 1.42 billion in the third, up 39.2% year on year. The company said manufacturing and SG&A cost ratios each improved by about 2 percentage points. It also cited cost-structure gains at its consolidated subsidiaries.

Overseas pipeline is advancing

After Thailand approved its botulinum toxin in June 2026, commercial shipments have started to feed into second-half results. China is preparing a marketing application and commercialization with its partner, and Brazil completed the inspection of the Wonju production site in July 2026.

Cash flow and margin recovery

Operating cash flow recovered to KRW 11.1 billion in 2025 from KRW 3.72 billion in 2024. Revenue reached KRW 76.9 billion in 2025 and has risen for three consecutive years since 2023. The operating margin was 5.0% in 2025, higher than 4.5% in 2023.

09

Bear factors

Persistent net losses for controlling shareholders

Net income attributable to controlling shareholders reached KRW 14 billion in 2023, then turned to a net loss of KRW 188 million in 2024. The 2025 net loss attributable to controlling shareholders widened to KRW 6.6 billion. The third-quarter 2026 net loss of KRW 3.81 billion was a wider loss than a year earlier.

Slower revenue momentum

Third-quarter 2026 revenue of KRW 18.9 billion fell 6.1% year on year. Cumulative revenue for the first three quarters of 2026 was KRW 54.98 billion, well short of the company's KRW 100 billion target for the year. Medical device items such as fillers fell 34% from the prior quarter in the first quarter of 2026.

Balance sheet and subsidiary burden

Total liabilities at the end of 2025 were KRW 144.1 billion, with a debt-to-equity ratio of 221.7%. All five consolidated subsidiaries were loss-making in the first quarter of 2026, and JETEMA USA INC. had the largest net loss at KRW 500 million. R&D spending in the same quarter was KRW 3.6 billion, or 22.7% of sales.

10

Risk factors

Approval timing risk

The China toxin approval, Brazil's ANVISA approval and the US Phase 3 trial all lack set timelines. Delays would push back the start of overseas sales growth. The company itself said approval timing and initial supply volumes will affect results.

Overseas partner dependence risk

Overseas sales account for 62.5% of revenue, and the China business relies on a local distribution partner. The partner's promotion and supply pace could determine how fast revenue grows. The execution of the five-year KRW 40 billion contract reported in 2025 is also a point to monitor.

Financial and cost risk

Total liabilities of KRW 144.1 billion and a debt-to-equity ratio of 221.7% represent a financial burden. The company attributed the 2025 operating profit decline to temporary expense increases and the wider net loss to lower tax benefits from deferred tax changes. If subsidiary losses persist, the pace of consolidated profit improvement will stay limited.

11

What to watch next

  1. Late March 2027

    Filing of the 2026 annual report. It will show whether the KRW 100 billion revenue target was met, along with the full-year operating margin and net result attributable to controlling shareholders, as filed figures.

  2. Mid-May 2027

    First-quarter 2027 quarterly report. Key points are how much Thai toxin commercial volume contributes to quarterly revenue and whether operating profit stays positive.

  3. After November 2026 (timing not set)

    Outcome of Brazil's ANVISA product approval. The procedure has been running since the July 2026 inspection of the Wonju plant, and approval timing and initial supply volume will shape overseas sales.

  4. After November 2026 (timing not set)

    Progress of the China botulinum toxin marketing application (BLA) and the commercialization schedule with the partner. The company names China as one of the markets that will determine overseas sales growth.

  5. After November 2026 (timing not set)

    Progress of the US botulinum toxin Phase 3 trial and whether global licensing out proceeds. These items underpin the company's long-term revenue ambition.

12

Overall view

Jetema's revenue rose to KRW 76.9 billion in 2025, up for three consecutive years. In 2026, operating profit swung from a first-quarter loss to positive results in the second and third quarters, showing a direction of profitability recovery.

On the other hand, the net loss attributable to controlling shareholders has persisted since 2024 and widened in the third quarter of 2026, and the debt-to-equity ratio of 221.7% is high.

With overseas sales at 62.5% of revenue, growth pace depends on whether Thai toxin shipments and China and Brazil approvals translate into reported results.

The company set a 2026 revenue target of KRW 100 billion, but cumulative revenue for the first three quarters was KRW 54.98 billion, so reaching the target requires a sharp shift in the remaining period.

On valuation, the price-to-earnings ratio cannot be calculated and the share price sits at a premium to book value, so whether profits persist is central to interpretation. Strengths include the operating profit run and the overseas pipeline, while weaknesses are persistent net losses and slowing revenue momentum.

The next checkpoints are the full-year results in the 2026 annual report and how much Thai volume appears in the first-quarter 2027 report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. medipharmhealth.co.kr
  2. thedailypost.kr
  3. specialtimes.co.kr
  4. press9.kr
  5. medifonews.com
  6. newspim.com
  7. news.nate.com
  8. medipana.com
  9. pharm.edaily.co.kr
  10. pharm.edaily.co.kr
  11. press9.kr
  12. thefairnews.co.kr
  13. m.yakup.com
  14. edaily.co.kr
  15. newspim.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis